Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetanus vaccination effects on immune mediators in multiple sclerosis
2007-001496-11Phase 2Terminated
- Sponsor
- University of Nottingham
- Start
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Revaxis in multiple sclerosis (MS), sponsored by University of Nottingham. Primary endpoint: Change in T-regulatory cells (Foxp3 expression). Started Mar 2010; status: terminated.
02
Drugs
Revaxis
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2007-001496-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001496-11.